Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases.

Pharmaceutics

School of Engineering and Sciences, Campus Querétaro, Tecnologico de Monterrey, Av. Epigmenio González, No. 500 Fracc. San Pablo, Querétaro 76130, Mexico.

Published: February 2023

AI Article Synopsis

  • - Neurodegenerative diseases (NDDs) lead to the gradual loss of neurons and are a significant global health concern, prompting the exploration of immunotherapies targeting harmful proteins linked to these conditions.
  • - Recent advancements in genetic engineering and molecular farming have enabled the development of plant-based systems to produce immunogenic vaccines aimed at treating major NDDs like Alzheimer's, Parkinson's, and multiple sclerosis.
  • - Plant-made vaccines have shown promise in preclinical studies by eliciting strong immune responses, and they offer several benefits such as scalability, safety from human pathogens, reduced need for cold storage, and lower production costs, highlighting their potential in combating NDDs.

Article Abstract

Neurodegenerative diseases (NDDs) are characterized by the progressive degeneration and/or loss of neurons belonging to the central nervous system, and represent one of the major global health issues. Therefore, a number of immunotherapeutic approaches targeting the non-functional or toxic proteins that induce neurodegeneration in NDDs have been designed in the last decades. In this context, due to unprecedented advances in genetic engineering techniques and molecular farming technology, pioneering plant-based immunogenic antigen expression systems have been developed aiming to offer reliable alternatives to deal with important NDDs, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Diverse reports have evidenced that plant-made vaccines trigger significant immune responses in model animals, supported by the production of antibodies against the aberrant proteins expressed in the aforementioned NDDs. Moreover, these immunogenic tools have various advantages that make them a viable alternative for preventing and treating NDDs, such as high scalability, no risk of contamination with human pathogens, cold chain free production, and lower production costs. Hence, this article presents an overview of the current progress on plant-manufactured vaccines for NDDs and discusses its future prospects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963606PMC
http://dx.doi.org/10.3390/pharmaceutics15020711DOI Listing

Publication Analysis

Top Keywords

neurodegenerative diseases
8
ndds
6
current advances
4
advances plant-based
4
plant-based vaccines
4
vaccines neurodegenerative
4
diseases neurodegenerative
4
diseases ndds
4
ndds characterized
4
characterized progressive
4

Similar Publications

Background: Patients with post-COVID condition (PCC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) experience symptoms potentially associated with small fiber neuropathy (SFN).

Methods: A sample of 90 participants, comprising 30 PCC patients, 30 ME/CFS patients, and 30 healthy controls (HC), matched by sex and age, was assessed. Neuropathic, autonomic, and fatigue symptoms were measured with TaskForce Monitor, the Sudoscan, heat and cold evoked potentials, In Vivo Corneal Confocal Microscopy (IVCCM), and specialized questionaries.

View Article and Find Full Text PDF

Agmatine suppresses glycolysis via the PI3K/Akt/mTOR/HIF-1α signaling pathway and improves mitochondrial function in microglia exposed to lipopolysaccharide.

Biofactors

January 2025

Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic"-National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.

Modulating metabolic pathways in activated microglia can alter their phenotype, which is relevant in uncontrolled neuroinflammation as a component of various neurodegenerative diseases. Here, we investigated how pretreatment with agmatine, an endogenous polyamine, affects metabolic changes in an in vitro model of neuroinflammation, a murine microglial BV-2 cell line exposed to lipopolysaccharide (LPS). Hence, we analyzed gene expression using qPCR and protein levels using Western blot and ELISA.

View Article and Find Full Text PDF

Do Novel Nonexercise and Nondrug Treatments Improve Global Cognition in Parkinson's Disease Patients? A Systematic Review and Bayesian Analysis.

Eur J Neurosci

February 2025

Department of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

This Bayesian network meta-analysis method was used to assess the effect of novel treatments on global cognition in patients with Parkinson's disease (PD). We searched randomized controlled trials from PubMed, Cochrane Library, Web of Science and Embase to investigate novel treatments for global PD cognition until April 10, 2024. Effect size measures were standardized mean differences with 95% confidence intervals.

View Article and Find Full Text PDF

Natural products against tau hyperphosphorylation-induced aggregates: Potential therapies for Alzheimer's disease.

Arch Pharm (Weinheim)

January 2025

Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana Cuajimalpa, Ciudad de México, Mexico.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory impairments and is considered the most prevalent form of dementia. Among the contributing factors to AD lies the hyperphosphorylation of the microtubule-associated protein tau. Phosphorylated tau reduces its affinity for microtubules and triggers other posttranslational modifications that result in its aggregation and assembly into filaments.

View Article and Find Full Text PDF

The Multifaceted Roles of BACH1 in Disease: Implications for Biological Functions and Therapeutic Applications.

Adv Sci (Weinh)

January 2025

Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Department of Rheumatology, Zhongshan Hospital, Zhongshan Hospital Immunotherapy Translational Research Center, Fudan University, Shanghai, 200032, China.

BTB domain and CNC homolog 1 (BACH1) belongs to the family of basic leucine zipper proteins and is expressed in most mammalian tissues. It can regulate its own expression and play a role in transcriptionally activating or inhibiting downstream target genes. It has a crucial role in various biological processes, such as oxidative stress, cell cycle, heme homeostasis, and immune regulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!